

Daniel Rooks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2931994/publications.pdf>

Version: 2024-02-01

13
papers

3,288
citations

840585

11
h-index

1199470

12
g-index

13
all docs

13
docs citations

13
times ranked

4826
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. Journal of the American Medical Directors Association, 2011, 12, 249-256.	1.2	2,427
2	Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. Journal of the American Geriatrics Society, 2020, 68, 1410-1418.	1.3	347
3	Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. Journal of the American Geriatrics Society, 2017, 65, 1988-1995.	1.3	165
4	Establishing the Link Between Lean Mass and Grip Strength Cut Points With Mobility Disability and Other Health Outcomes: Proceedings of the Sarcopenia Definition and Outcomes Consortium Conference. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1317-1323.	1.7	91
5	Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults. JAMA Network Open, 2020, 3, e2020836.	2.8	71
6	Bimagrumab improves body composition and insulin-resistant individuals. Diabetes, Obesity and Metabolism, 2018, 20, 94-102.	2.2	59
7	Continuous Digital Monitoring of Walking Speed in Frail Elderly Patients: Noninterventional Validation Study and Longitudinal Clinical Trial. JMIR MHealth and UHealth, 2019, 7, e15191.	1.8	39
8	DEVELOPMENT OF PHARMACOTHERAPIES FOR THE TREATMENT OF SARCOPENIA. Journal of Frailty & Aging, 2019, 8, 1-11.	0.8	31
9	Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations. Therapeutic Innovation and Regulatory Science, 2019, 53, 146-153.	0.8	24
10	Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clinical Endocrinology, 2018, 88, 908-919.	1.2	18
11	Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1525-1534.	2.9	15
12	Sarcopenia: a Muscle Disease with Decreased Functional Capacity and an Increased Risk of Adverse Health Outcomes. Current Physical Medicine and Rehabilitation Reports, 2019, 7, 290-296.	0.3	1
13	Reply to: New Hope for Sarcopenia. Journal of the American Geriatrics Society, 2018, 66, 208-209.	1.3	0